Ozempic (semaglutide) is FDA-approved and considered safe for most people with type 2 diabetes, but it carries real risks that range from common digestive side effects to rare but serious complications. The safety picture depends heavily on your individual health history, particularly whether you have a personal or family history of certain thyroid cancers, a history of pancreatitis, or are pregnant or planning to become pregnant.
Here’s what the clinical evidence actually shows about the risks and benefits.
How Ozempic Works in Your Body
Semaglutide mimics a natural hormone your gut releases after eating. It increases insulin production when your blood sugar is high, reduces the amount of sugar your liver dumps into your bloodstream, and slows digestion so food moves through your stomach more gradually. That slower digestion is central to how the drug works, but it’s also the source of many of its side effects.
Common Side Effects
The most frequent complaints are gastrointestinal: nausea, vomiting, diarrhea, constipation, and stomach pain. These tend to be worst during the first weeks of treatment and during dose increases, then gradually improve as your body adjusts. Most people find these symptoms manageable, but a meaningful percentage of trial participants stopped taking the drug because of them.
Nausea is by far the most reported side effect. Eating smaller meals, avoiding fatty or greasy foods, and staying hydrated can help. Your prescriber will typically start you on a low dose and increase it gradually specifically to minimize these effects.
The Thyroid Cancer Warning
Ozempic carries the FDA’s most serious warning, a boxed warning, about the risk of a rare type of thyroid cancer called medullary thyroid carcinoma. In animal studies, semaglutide caused thyroid tumors in rodents. Whether this translates to humans isn’t fully established, but the FDA treats it as a genuine concern.
Ozempic is completely off-limits if you have a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. If you notice a lump or swelling in your neck, difficulty swallowing, or persistent hoarseness while taking the drug, those warrant prompt medical attention.
Pancreatitis Risk
Acute pancreatitis, a painful inflammation of the pancreas, has been reported in people taking semaglutide. In a clinical trial evaluating semaglutide for weight loss, 3 out of 1,306 participants developed acute pancreatitis, while none of the 655 people taking a placebo did. That’s a low absolute number, but the imbalance is notable.
Severe, persistent abdominal pain that radiates to your back, especially with vomiting, is the hallmark symptom. If you’ve had pancreatitis before, the risk-benefit conversation with your prescriber becomes more important.
Stomach Paralysis and Digestive Complications
Because semaglutide deliberately slows digestion, there’s a question about where “slowed digestion” ends and “stomach paralysis” begins. Gastroparesis, a condition where the stomach can’t empty properly, has been linked to these drugs. A large study examining insurance records of roughly 16 million U.S. patients found that people taking semaglutide or similar drugs had 3.67 times the risk of gastroparesis compared to people taking a different weight-loss medication.
Gastroparesis symptoms include persistent nausea, vomiting, bloating, and abdominal pain that goes beyond the typical adjustment-period discomfort. These events are considered rare on an individual level, but with millions of people now taking GLP-1 drugs, even a small percentage translates to a large number of affected people.
Heart Health: A Genuine Benefit
One of the clearest safety signals runs in Ozempic’s favor. In the SUSTAIN-6 trial, which followed more than 3,200 people with type 2 diabetes for two years, major cardiovascular events (heart attack, stroke, or cardiovascular death combined) occurred in 6.6% of the semaglutide group versus 8.9% of the placebo group. That’s a 26% relative risk reduction. Nonfatal strokes were 39% less likely in the semaglutide group.
Rates of death from cardiovascular causes were similar between groups, so the benefit appears to be primarily in preventing heart attacks and strokes rather than extending overall survival. Still, for people with type 2 diabetes who are already at elevated cardiovascular risk, this is a meaningful protective effect.
Suicidal Thoughts: What the Data Shows
Early reports raised concerns about a possible link between GLP-1 drugs and suicidal thoughts. The FDA investigated this thoroughly, conducting a meta-analysis of 91 placebo-controlled trials covering nearly 108,000 patients and a separate real-world study of over 2.2 million medication users. Neither analysis found an increased risk of suicidal ideation, self-harm, depression, anxiety, or psychosis.
Based on these findings, the FDA actually requested that manufacturers remove the suicidal behavior warning from the labeling of semaglutide and similar drugs. This is one area where a worry that gained traction in the media turned out not to be supported by the data.
Muscle Loss During Weight Loss
This concern doesn’t get enough attention. In the STEP-1 trial, people taking semaglutide lost an average of 15.3 kg (about 34 pounds), but roughly 6.9 kg of that was lean mass, not fat. That means about 45% of the total weight lost came from muscle and other lean tissue. Normally, when people lose weight through diet alone, about 25% of what they lose is lean mass. Semaglutide nearly doubled that ratio.
Losing muscle matters because it affects your metabolism, strength, balance, and long-term ability to keep weight off. Resistance training and adequate protein intake while on the medication can help preserve muscle, and many prescribers now emphasize this as part of treatment. If you’re older or already have low muscle mass, this tradeoff deserves serious consideration.
Pregnancy and Fertility
Ozempic is not considered safe during pregnancy. Animal studies have shown harmful effects on developing embryos, and there isn’t enough human data to confirm safety. The drug can also increase fertility indirectly: weight loss and improved insulin sensitivity can restore ovulation in people who weren’t ovulating regularly, which has led to unplanned pregnancies, sometimes called “Ozempic babies” in the media.
If you’re planning to become pregnant, a washout period between stopping the drug and conceiving is recommended. Semaglutide has a long half-life, meaning it stays active in your body for weeks after your last injection. Reliable contraception while taking Ozempic is important if pregnancy isn’t part of your plan, and the drug should be stopped well in advance if it is.
Who Should Be Most Cautious
Several groups face higher risk profiles with Ozempic:
- People with a history of pancreatitis may face a recurrence.
- Anyone with a family history of medullary thyroid carcinoma or MEN 2 should not take the drug at all.
- People with diabetic retinopathy should be monitored closely, as the SUSTAIN-6 trial found higher rates of retinopathy complications in the semaglutide group.
- People with a history of severe gastrointestinal conditions may be more susceptible to gastroparesis or bowel obstruction.
- Older adults or those with low muscle mass should weigh the disproportionate lean tissue loss against the benefits of weight reduction.
For people with type 2 diabetes and cardiovascular risk factors, the safety profile tilts favorably. The heart benefits are well-documented, the most common side effects are temporary and manageable, and the serious risks, while real, are statistically uncommon. The calculus shifts depending on what you’re treating, what other health conditions you have, and how long you plan to stay on the medication.